HYFT · MindWalk Holdings Corp.

Summary

MindWalk Holdings Corp. announced B Cell Llama™, a nanobody discovery platform for VHH single-domain antibodies optimized for bispecific antibodies and cell therapies, supported by a peer-reviewed study in ACS Biomacromolecules demonstrating enhanced potency, resistance defeat, and immune-priming potential. MindWalk holds first right to commercialize jointly developed IP from the collaboration.

Key takeaways

• Announced B Cell Llama™ platform extending B Cell Select® for llama-derived VHH nanobodies.
• Peer-reviewed study in Biomacromolecules (2026, 27(2), 1446-1458) shows multivalent VHH nanobodies achieve sub-nanomolar potency, 10-25x greater than monovalent.
• Trivalent VHH construct neutralized variants escaping monovalent formats and approved antibody therapies.
• VHH-nanoparticle complexes preferentially internalized by immune cells for long-term memory.
• Collaboration with Eindhoven University of Technology and Radboud University Medical Center; MindWalk has first right to commercialize IP.
• Technologies supported advancement of over 15 molecules to clinic; current programs include dengue, universal influenza, GLP-1, longevity, ALK-1.